PE20211290A1 - Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad del parkinson - Google Patents
Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad del parkinsonInfo
- Publication number
- PE20211290A1 PE20211290A1 PE2020000566A PE2020000566A PE20211290A1 PE 20211290 A1 PE20211290 A1 PE 20211290A1 PE 2020000566 A PE2020000566 A PE 2020000566A PE 2020000566 A PE2020000566 A PE 2020000566A PE 20211290 A1 PE20211290 A1 PE 20211290A1
- Authority
- PE
- Peru
- Prior art keywords
- disease
- parkinson
- treatment
- propyl
- propharmacs
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- HZPDHOOVQQYBJP-TZMCWYRMSA-N (4ar,10ar)-1-propyl-3,4,4a,5,10,10a-hexahydro-2h-benzo[g]quinoline-6,7-diol Chemical compound C1=CC(O)=C(O)C2=C1C[C@H]1N(CCC)CCC[C@@H]1C2 HZPDHOOVQQYBJP-TZMCWYRMSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000005793 Restless legs syndrome Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A COMPUESTOS DE FORMULA (Id) QUE SON PROFARMACOS DEL AGONISTA DE DOPAMINA (4AR,10AR)-1-N-PROPIL-1,2,3,4,4A,5,10,10A-OCTAHIDRO-BENZO[G]QUINOLINA-6,7-DIOL DONDE R1 Y R2 SON COMO SE DEFINEN EN LA DESCRIPCION. SON COMPUESTOS PREFERIDOS: ACIDO (2S,3S,4S,5R,6S)-3,4,5-TRIHIDROXI-6-(((4AR,10AR)-7-HIDROXI-1-PROPIL-1,2,3,4,4A,5,10,10A-OCTAHIDROBENZO[G]QUINOLIN-6-IL)OXI)TETRAHIDRO-2H-PIRAN-2-CARBOXILICO; ACIDO (2S,2'S,3S,3'S,4S,4'S,5R,5'R,6S,6'S)-6,6'-(((4AR,10AR)-1-PROPIL-1,2,3,4,4A,5,10,10A-OCTAHIDROBENZO[G]QUINOLINO-6,7-DIIL)BIS(OXI))BIS(3,4,5-TRIHIDROXITETRAHIDRO-2H-PIRAN-2-CARBOXILICO); ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON, ENFERMEDAD DE HUNTINGTON, SINDROME DE LAS PIERNAS INQUIETAS, ENFERMEDAD DE ALZHEIMER.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201700674 | 2017-11-24 | ||
PCT/EP2018/082361 WO2019101917A1 (en) | 2017-11-24 | 2018-11-23 | New catecholamine prodrugs for use in the treatment of parkinson's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20211290A1 true PE20211290A1 (es) | 2021-07-20 |
Family
ID=64661284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2020000566A PE20211290A1 (es) | 2017-11-24 | 2018-11-23 | Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad del parkinson |
Country Status (25)
Country | Link |
---|---|
US (4) | US10729710B2 (es) |
EP (1) | EP3713933A1 (es) |
JP (4) | JP7320507B2 (es) |
KR (1) | KR20200092955A (es) |
CN (3) | CN117653649A (es) |
AR (1) | AR113908A1 (es) |
AU (2) | AU2018371193B2 (es) |
BR (1) | BR112019014981A2 (es) |
CA (1) | CA3082757A1 (es) |
CL (1) | CL2020001343A1 (es) |
CO (1) | CO2020006224A2 (es) |
CR (1) | CR20200225A (es) |
EA (1) | EA202090987A8 (es) |
EC (1) | ECSP20030074A (es) |
GE (1) | GEP20227446B (es) |
IL (1) | IL274648B1 (es) |
JO (1) | JOP20200114A1 (es) |
MA (1) | MA50800A (es) |
MX (2) | MX2020005366A (es) |
PE (1) | PE20211290A1 (es) |
PH (1) | PH12020550631A1 (es) |
SG (1) | SG11202004461YA (es) |
TW (1) | TWI816716B (es) |
UA (1) | UA127575C2 (es) |
WO (1) | WO2019101917A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7320507B2 (ja) | 2017-11-24 | 2023-08-03 | ハー・ルンドベック・アクチエゼルスカベット | パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ |
US11130775B2 (en) | 2019-05-20 | 2021-09-28 | H. Lundbeck A/S | Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
US11104697B2 (en) | 2019-05-20 | 2021-08-31 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
US11168056B2 (en) | 2019-05-20 | 2021-11-09 | H. Lundbeck A/S | Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol |
US11111263B2 (en) | 2019-05-20 | 2021-09-07 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
US20220213136A1 (en) | 2019-05-21 | 2022-07-07 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's diseases |
WO2020234274A1 (en) | 2019-05-21 | 2020-11-26 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's disease |
US20220220077A1 (en) * | 2019-05-21 | 2022-07-14 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's disease |
US20240025857A1 (en) | 2020-11-17 | 2024-01-25 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's disease |
WO2023208865A1 (en) | 2022-04-25 | 2023-11-02 | Integrative Research Laboratories Sweden Ab | NOVEL 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF |
WO2023208867A1 (en) | 2022-04-25 | 2023-11-02 | Integrative Research Laboratories Sweden Ab | NOVEL 1,2,3,4,4a,5,8,9,10,10a-DECAHYDROBENZO[G]QUINOLIN-6(7H)-ONE COMPOUNDS AND USES THEREOF |
WO2023208869A1 (en) | 2022-04-25 | 2023-11-02 | Integrative Research Laboratories Sweden Ab | NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF |
WO2023242355A1 (en) | 2022-06-15 | 2023-12-21 | Ever Neuro Pharma Gmbh | Apomorphine prodrugs and uses thereof |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3132171A (en) | 1962-06-18 | 1964-05-05 | Strong Cobb Arner Inc | 3, 4-diphosphatophenyl-alanine and process for making same |
US4543256A (en) | 1982-03-17 | 1985-09-24 | Northeastern University | (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers |
ATE56958T1 (de) | 1981-10-16 | 1990-10-15 | Sandoz Ag | 1,2,3,4,4a,5,10,10a-octahydrobenzo(g)chinolinderivate mit pharmazeutischer wirkung. |
PH22782A (en) | 1983-02-01 | 1988-12-12 | Sandoz Ltd | Novel pharmaceutical active 1,2,3,4,4a,5,10,10a octahydrobenzo(g)quinoline derivatives |
JPS60172975A (ja) | 1984-02-15 | 1985-09-06 | Sumitomo Chem Co Ltd | エリスロ−3−(3,4−メチレンジオキシフエニル)セリンの製造方法 |
GB2192394A (en) | 1986-07-11 | 1988-01-13 | Glaxo Group Ltd | Amine derivatives |
IT1226727B (it) | 1988-07-29 | 1991-02-05 | Simes | Farmaci precursori della dopamina. |
ATE118216T1 (de) | 1989-04-20 | 1995-02-15 | Zambon Spa | Dopamin-medikament-vorstufe. |
WO1990012574A1 (en) | 1989-04-25 | 1990-11-01 | Northeastern University | Dopamine agonist compounds |
IT1271411B (it) | 1993-09-14 | 1997-05-28 | Zambon Spa | Derivati del 2-ammino-1,2,3,4-tetraidro-naftalene attivi sul sistema cardiovascolare |
US5955468A (en) | 1993-12-21 | 1999-09-21 | Sandoz Ltd. | Benzo G!quinolines for use in prevention or delay of progressive atrophy of the optic nerve |
TW357143B (en) | 1995-07-07 | 1999-05-01 | Novartis Ag | Benzo[g]quinoline derivatives |
IT1289979B1 (it) | 1997-02-26 | 1998-10-19 | Zambon Spa | 5-idrossimetil-6-idrossi-2-amminotetraline attive come agenti cardiovascolari |
GB9902938D0 (en) | 1999-02-10 | 1999-03-31 | Novartis Ag | Organic compounds |
CO5261532A1 (es) | 1999-11-15 | 2003-03-31 | Novartis Ag | Compuestos heterociclicos sililados, procedimiento para la preparacion de estos y composicion farmaceutica que los contiene |
HUP0301773A3 (en) | 2000-04-07 | 2006-02-28 | Tap Pharmaceutical Prod Inc | Apomorphine derivatives and methods for their use |
SE0001438D0 (sv) | 2000-04-18 | 2000-04-18 | Axon Chemicals Bv | New chemical compounds and their use in therapy |
AU8824201A (en) | 2000-08-11 | 2002-02-25 | Bristol Myers Squibb Co | Process for the preparation of dinapsoline |
SE0102036D0 (sv) | 2001-06-08 | 2001-06-08 | Axon Biochemicals Bv | Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof |
PE20030240A1 (es) | 2001-07-09 | 2003-04-16 | Novartis Ag | DERIVADOS DE BENZO [g] QUINOLINA |
WO2003013532A1 (en) | 2001-08-10 | 2003-02-20 | Purdue Research Foundation | Chiral dinapsoline |
EG24415A (en) | 2002-03-07 | 2009-05-25 | Novartis Ag | Quinoline derivatives |
JP2005526790A (ja) | 2002-03-19 | 2005-09-08 | ミシェル ホリック | アポモルフィンおよび類縁体の配糖体およびオルトエステル配糖体誘導体、ならびにそれらの使用方法 |
WO2004052841A1 (en) | 2002-12-06 | 2004-06-24 | Xenoport, Inc. | Carbidopa prodrugs and uses thereof |
WO2005062894A2 (en) | 2003-12-23 | 2005-07-14 | Darpharma, Inc. | Co-administration of dopamine-receptor binding compounds |
WO2006012640A2 (en) | 2004-07-21 | 2006-02-02 | Darpharma, Inc. | Method of administration of dopamine receptor agonists |
WO2006056604A1 (en) | 2004-11-25 | 2006-06-01 | Evolva Ag | Levodopa glycosyl derivatives, methods of preparation and use |
US8129530B2 (en) | 2007-08-31 | 2012-03-06 | H. Lundbeck A/S | Catecholamine derivatives and prodrugs thereof |
TWI404702B (zh) * | 2007-08-31 | 2013-08-11 | Lundbeck & Co As H | 兒茶酚胺衍生物和其前藥 |
TW201036949A (en) * | 2009-02-27 | 2010-10-16 | Lundbeck & Co As H | Treatment of dyskinesia related disorders |
TW201035054A (en) | 2009-02-27 | 2010-10-01 | Lundbeck & Co As H | Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof |
EP2557079A1 (en) | 2011-08-09 | 2013-02-13 | Nestec S.A. | Synthesis of catechin and epicatechin conjugates |
DE102011112496A1 (de) | 2011-09-07 | 2013-03-07 | Thanares GmbH | 4-Methylcatecholderivate und deren Verwendung |
CN102746351B (zh) | 2012-07-23 | 2018-03-02 | 上海弈柯莱生物医药科技有限公司 | 灯盏花乙素及其类似物的制备方法 |
GB201319768D0 (en) | 2013-11-08 | 2013-12-25 | Glycosynth Ltd | Naphthalene derived chromogenic enzyme substrates |
EP4186510A1 (en) | 2014-10-21 | 2023-05-31 | AbbVie Inc. | Intermediates and process for preparing l-dopa diphosphate |
CN105218606B (zh) | 2015-10-19 | 2017-12-01 | 昆明理工大学 | 一种制备灯盏乙素的方法 |
EP4295909A2 (en) | 2016-04-20 | 2023-12-27 | AbbVie Inc. | Carbidopa and l-dopa prodrugs and methods of use |
US9920342B2 (en) | 2016-05-17 | 2018-03-20 | Divi's Laboratories Limited | Process for the preparation of Droxidopa |
JP7320507B2 (ja) * | 2017-11-24 | 2023-08-03 | ハー・ルンドベック・アクチエゼルスカベット | パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ |
US11104697B2 (en) | 2019-05-20 | 2021-08-31 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
US11111263B2 (en) | 2019-05-20 | 2021-09-07 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
US11168056B2 (en) | 2019-05-20 | 2021-11-09 | H. Lundbeck A/S | Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol |
US11130775B2 (en) | 2019-05-20 | 2021-09-28 | H. Lundbeck A/S | Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
US20220220077A1 (en) | 2019-05-21 | 2022-07-14 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's disease |
US20220213136A1 (en) | 2019-05-21 | 2022-07-07 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's diseases |
WO2020234274A1 (en) | 2019-05-21 | 2020-11-26 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's disease |
EP3972600A1 (en) | 2019-05-21 | 2022-03-30 | H. Lundbeck A/S | Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease |
JP2023013012A (ja) * | 2021-07-15 | 2023-01-26 | 株式会社日立製作所 | 運行提案システム、及び運行提案作成方法 |
-
2018
- 2018-11-23 JP JP2020528199A patent/JP7320507B2/ja active Active
- 2018-11-23 US US16/198,917 patent/US10729710B2/en active Active
- 2018-11-23 JO JOP/2020/0114A patent/JOP20200114A1/ar unknown
- 2018-11-23 KR KR1020207014479A patent/KR20200092955A/ko not_active Application Discontinuation
- 2018-11-23 UA UAA202003060A patent/UA127575C2/uk unknown
- 2018-11-23 EA EA202090987A patent/EA202090987A8/ru unknown
- 2018-11-23 CR CR20200225A patent/CR20200225A/es unknown
- 2018-11-23 AR ARP180103436A patent/AR113908A1/es unknown
- 2018-11-23 AU AU2018371193A patent/AU2018371193B2/en active Active
- 2018-11-23 GE GEAP201815342A patent/GEP20227446B/en unknown
- 2018-11-23 PE PE2020000566A patent/PE20211290A1/es unknown
- 2018-11-23 TW TW107141799A patent/TWI816716B/zh active
- 2018-11-23 MA MA050800A patent/MA50800A/fr unknown
- 2018-11-23 CN CN202311564635.XA patent/CN117653649A/zh active Pending
- 2018-11-23 IL IL274648A patent/IL274648B1/en unknown
- 2018-11-23 CN CN201880075320.XA patent/CN111386267B/zh active Active
- 2018-11-23 EP EP18815537.8A patent/EP3713933A1/en active Pending
- 2018-11-23 CN CN202311564502.2A patent/CN117599073A/zh active Pending
- 2018-11-23 CA CA3082757A patent/CA3082757A1/en active Pending
- 2018-11-23 MX MX2020005366A patent/MX2020005366A/es unknown
- 2018-11-23 WO PCT/EP2018/082361 patent/WO2019101917A1/en active Application Filing
- 2018-11-23 SG SG11202004461YA patent/SG11202004461YA/en unknown
- 2018-11-23 BR BR112019014981A patent/BR112019014981A2/pt unknown
-
2020
- 2020-05-12 US US16/872,802 patent/US11110110B2/en active Active
- 2020-05-14 PH PH12020550631A patent/PH12020550631A1/en unknown
- 2020-05-20 CL CL2020001343A patent/CL2020001343A1/es unknown
- 2020-05-21 CO CONC2020/0006224A patent/CO2020006224A2/es unknown
- 2020-06-03 EC ECSENADI202030074A patent/ECSP20030074A/es unknown
- 2020-07-13 MX MX2022016276A patent/MX2022016276A/es unknown
-
2021
- 2021-07-28 US US17/386,686 patent/US11707476B2/en active Active
-
2023
- 2023-01-31 JP JP2023013012A patent/JP7320684B2/ja active Active
- 2023-03-21 AU AU2023201741A patent/AU2023201741A1/en not_active Abandoned
- 2023-06-06 US US18/330,293 patent/US20240156851A1/en active Pending
- 2023-07-24 JP JP2023119693A patent/JP7443606B2/ja active Active
- 2023-07-24 JP JP2023119694A patent/JP2023145580A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20211290A1 (es) | Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad del parkinson | |
DOP2018000257A (es) | Piridinas sustituidas con heteroarilo y métodos de uso | |
ECSP12011631A (es) | Composición de insulina de acción prolongada | |
UY32259A (es) | Nuevos compuestos de hidroxiareno, preparados farmaceuticos que los contienen y aplicaciones | |
UY32611A (es) | Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
CO6470845A2 (es) | Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales | |
ECSP14004812A (es) | Triazolopiridinas sustituidas | |
CO6341623A2 (es) | Compuestos organicos | |
CO6620055A2 (es) | Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos | |
CO6270324A2 (es) | Derivados de pirimidina para el tratamiento del asma epoc rinitis conjutivitis alergica dermatitis atopica cancer hepatitis b hepatitis c vih vph infecciones bacterianas y dermatosis | |
CO6771439A2 (es) | Inhibidores de benzodioxano de la producción de leucotrieno | |
CO7310531A2 (es) | 4-metil-2,3,8,9,9b-pentaaza-ciclopenta [a] naftalenos | |
UY29988A1 (es) | Compuestos de oxazolidinona y su uso como potenciadores del receptor metabotrópico de glutamato | |
UY32240A (es) | Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones. | |
UY32494A (es) | Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones | |
GT201600091A (es) | Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos | |
UY29343A1 (es) | Pirazolopiridinas y sales de las mismas, una composición farmacéutica que comprende dichos compuestos, un método para prepararlos y su uso. | |
CL2017000293A1 (es) | Compuestos derivados de benzofurano sustituido en posición 6 por un radical que contiene boro; composición farmacéutica que los comprende; uso en el tratamiento de la hepatitis c (divisional del cl 393-2014) | |
CR20130569A (es) | Análogos del ácido epoxieicosatrienoicos y métodos de toma y uso del mismo | |
ECSP11010816A (es) | Nuevos Compuestos | |
AR116001A2 (es) | Composición farmacéutica 271 | |
ECSP14026432A (es) | (r)-nifuratel y síntesis de (r) y (s)-nifuratel | |
CO6290768A2 (es) | Tiazolil-dihidro-indazoles | |
UY32744A (es) | Derivados de 2-carboxamida-7-piperazinil-benzofurano 774 | |
CO6460762A2 (es) | 5-alquinil-piridinas |